Series A · Biotech
Orakl Oncology raises $34 million Series A for AI cancer-drug testing
Norrsken VC and Singular co-led the round for the French company, which combines patient-derived tumour models with AI to guide drug development.
Orakl Oncology has raised a $34 million Series A co-led by Norrsken VC and Singular, Sifted reported on 12 November 2026. The company develops AI-powered models of cancer patients to help pharmaceutical teams assess experimental treatments before clinical trials.
Its approach combines organoids grown from patients’ tumours with drug-response experiments, molecular measurements and clinical histories. These linked biological and computational models underpin tools for predicting treatment response, selecting patients and identifying therapeutic targets.
Funding history
Series A · This round$34M